Get access

Maternal characteristics and migraine pharmacotherapy during pregnancy: cross-sectional analysis of data from a large cohort study

Authors

  • K Nezvalová-Henriksen,

    Corresponding author
    1. Department of Pharmacy, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo,
      Kateřina Nezvalová-Henriksen, Department of Pharmacy, Faculty of Mathematics and Natural Sciences, University of Oslo, PO Box 1065 Blindern, Oslo, N-0316, Norway. Tel. + 47-2284-4761, fax + 47-2285-4402, e-mail k.n.henriksen@farmasi.uio.no
    Search for more papers by this author
  • O Spigset,

    1. Department of Clinical Pharmacology, St Olav's University Hospital and
    2. Department of Laboratory Medicine, Children's and Women's Health, Norwegian University of Science and Technology, Trondheim, and
    Search for more papers by this author
  • H Nordeng

    1. Department of Pharmacy, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo,
    2. The Division for Mental Health, National Institute of Health, Oslo, Norway
    Search for more papers by this author

Kateřina Nezvalová-Henriksen, Department of Pharmacy, Faculty of Mathematics and Natural Sciences, University of Oslo, PO Box 1065 Blindern, Oslo, N-0316, Norway. Tel. + 47-2284-4761, fax + 47-2285-4402, e-mail k.n.henriksen@farmasi.uio.no

Abstract

Nezvalová-Henriksen K, Spigset O & Nordeng H. Maternal characteristics and migraine pharmacotherapy during pregnancy: cross-sectional analysis of data from a large cohort study. Cephalalgia 2009. London. ISSN 0333-1024

Little is known about factors associated with migraine pharmacotherapy during pregnancy. Of 60 435 pregnant women in a population-based cohort, 3480 (5.8%) reported having migraine during the first 5 months of pregnancy. Of these, 2525 (72.6%) reported using migraine pharmacotherapy, mostly non-narcotic analgesics (54.1%) and triptans (25.4%). After adjustment for sociodemographic factors and comorbidities in logistic regression analysis, high pregestational body mass index [odds ratio (OR) 1.3, 95% confidence interval (CI) 1.2, 1.4], sleep < 5 h (OR 1.6, 95% CI 1.3, 1.9), being on sick-leave (OR 1.3, 95% CI 1.2, 1.5) and acute back/shoulder/neck pain (OR 0.6, 95% CI 0.6, 0.7) were associated with migraine pharmacotherapy during pregnancy. Many women need drug treatment for migraine during pregnancy, and the choice of pharmacotherapy during this period may be influenced by maternal sociodemographic factors and comorbidities.

Get access to the full text of this article

Ancillary